Articles About Medtech

Everyone Is Wrong Once Again About Teledoc – Here’s How We’re Turning Those Mistakes Into Our Gains

0 | By Michael A. Robinson

On August 25, 2020, I said that there was a fire sale you as a savvy tech investor could take advantage of with Teledoc Health Inc. (TDOC).

Wall Street analysts were worried about Teledoc buying Livongo Health Inc. (LVGO) and the $18.5 billion price tag. But I know this was a big move that would add to TDOC’s lead in the shift to telemedicine.

Livongo makes devices that allow healthcare providers to remotely monitor health metrics such as blood pressure, blood sugar, weight, even behavioral health. Together they allow physicians and nurses to speak to patients remotely while having the most up-to-date information on their health.

I made it clear back then that I expected Teledoc Health Inc. (TDOC) to bounce back and beat the market.

From the day shares hit a bottom on November 10 to its recent high on February 19, TDOC zoomed some 69.6%.

Over that period, it crushed the S&P 500 by a stunning 640%.

Now, history is repeating itself, and this massive profit opportunity is coming back around. The stock is grossly oversold once again, and I see a similar setup in the making as the firm disrupts the $1.3 trillion medical market.

Here’s the thing.

According to a survey from The Harris Poll, 65% of consumers surveyed plan to use telehealth services more often after the pandemic, putting paid to Wall Street’s ridiculous notion that we’re just itching to go back to the doctor’s office.

This is still a move well worth making.

Let me show you what’s really going on and how you can clean up from Wall Street’s mistake…

Wall Street is Counting Out the Biggest Breakthrough in Medicine – Here’s How to Make Their Mistake into Your Gain

0 | By Michael A. Robinson

When Wall Street overreacts and goes right, you can make a fortune by avoiding the noise and going in the opposite direction.

In the latest edition of wild overreactions, Cathie Wood, the top-notch ETF manager of Ark Investment Management, received some flak from The Wall Street Journal.

I’ll have more on that in just a bit and why it is totally off the mark.

But make no mistake. Wood has an uncanny eye for finding breakout stocks with a market-beating track record to prove it.

One particular feather in Wood’s cap is an ETF that she runs focusing on the cutting-edge field of genomics, a tech that basically didn’t exist just a decade ago.

Without genomics, we wouldn’t have been able to understand the structure of the coronavirus. Not only that, but the first two vaccines approved both relied on a hot new segment of genomics.

And this is an industry that is projected to multiply from $18.85 billion in 2019 to $82.60 billion in 2027, according to Fortune Business Insights. That’s more than 300% growth in less than a decade.

I’ll give you more details in a moment. But first, I want to point out the sizzling returns that Wood has amassed.

Over roughly the past year, Wood’s fund beat the market by a stunning 471%.

Let me show you why this play is just getting started…

The Perfect Small Stock for Playing the $72 Billion Digital Healthcare Sector

0 | By Alex Kagin

Of all the changes the ongoing coronavirus pandemic forced on us, the change in healthcare has got to be one of the most profound.

Whether we’re managing a chronic condition, like high blood pressure, say, or an acute illness like strep throat, the market demand for healthcare needs hasn’t decreased a bit, but COVID-19 has made getting in to see a primary or specialist physician a lot more complicated and, in some cases, a lot riskier.

That means telemedicine, and the broader field of digital healthcare, are the name of the game right now. The $20 billion Teledoc-Livongo merger is proof of that.

Continue reading…

This Med-Tech Breakthrough Nearly Tripled the Market’s Returns, And It’s About to Go Even Higher

0 | By Michael A. Robinson

A very profitable chat we had back on May 19 is coming up on another chance to pay off right now

At the time I told you about a medical device leader that had just received approval for a Covid-19 test, and shot up 120% in two months.

But this is not just a COVID testing play. From early 2019 through this past February’s correction, this stock was outperforming the S&P 500 by an astonishing 278.5%.

This firm is a leader in the medical device market as part of a trend toward remote patient monitoring that’s been supercharged by the COVID pandemic.

With the coronavirus surging once again, the investment thesis is only getting better.

Today, I will reveal the name of this market crushing leader and show you why there ‘s still so much upside ahead…

Americans Have A New Way of Dealing with Lockdowns – And It’s Supercharging the Market for This Company’s Products

0 | By Michael A. Robinson

Hearing that two of my neighbors had each gotten a new dog in one week may not sound like much.

But to me, those were important data points in a much larger trend. According to TD Ameritrade, 33% of Americans have considered getting a new pet to help keep them company amidst COVID restrictions.

They actually spell Big Money for savvy tech investors – if you know where to look.

I know this from personal experience. I follow the animal health care market because my dog, Roxy, has a bit of arthritis and may soon need to start a course of drugs.

And this knowledge can not only help America’s pet owners care for their companions but also find the hidden profit potential in animal healthcare technology.

It’s a growing market, as with much of the nation still working or attending school from home, demand for dogs is booming.

Consider that the U.S alone already boasts 300 million pets. Related health care on a global basis last year will soon be worth $327 billion.

Today, I’m going to reveal a leader in this key field of animal science that’s proven it can outperform the broader market by 50%…

This Life-Saving Breakthrough Is Saving COVID Patient’s Hearts and Giving You The Opportunity To Take Advantage Of A Projected $600 Billion Industry

1 | By Michael A. Robinson

Devan Smith had one foot in the grave.

After contracting COVID-19 last May, he was hospitalized with severe respiratory issues and multiorgan failure.

And if that wasn’t bad enough, the 42-year Pennsylvania warehouse worker also had to deal with a malfunctioning heart. That alone could have killed him.

But doctors at the Mercy Catholic Medical Center in Pennsylvania were able to save Smith in no small measure because of a tiny heart pump.

Known as the Impella, that device received an emergency use authorization from the FDA to treat coronavirus patients only weeks before.

Of course, Smith credits the medical team with saving his life. But he’s quick to point out that the Impella played a big role in it all.

And Bill is not alone.

These kinds of heart complications are reported to affect as many as 10% of COVID-19 patients.

Fortunately for tech investors, there’s a lot more going on here than a feel-good feature story.

The medical device market is worth $625 billion, and the company behind Impella can grab a big chunk of that.

And make you a lot of money…

There’s a “Silent Partner” In the Project for A Post-COVID America – And You Can Buy It At A Great Discount

2 | By Michael A. Robinson

The best minds in biotech are working round the clock on putting a stop to the COVID-19 pandemic. The project includes over 135 vaccine candidates and the profit potential here is massive.

This is literally about saving the world.

The thing is, though, vaccines are only one part of this project. There’s another dimension, a “silent partner” in the project that doesn’t get quite so much heroic headline ink but is just as important.

You see, of all the vaccines coming down the pipeline, 31 are currently in human trials. There’s a very good chance that one of them will be safe and powerful enough to begin mass distribution in early 2021.

But there are 328 million living Americans and 7.5 billion humans on planet earth. It will take time to vaccinate them all, and that’s where our “silent partner” comes in.

It’s blazing a trail towards the kind of better COVID-19 testing technology we will need to get things fully back to normal.

And not only that, it’s on a solid track to double your money in just two years…

The Doctor’s Office Visit Is History, and What Comes Next Could Make You A Fortune

1 | By Michael A. Robinson

Looking for a parking spot for 15 minutes, spending 20 minutes filling out forms, and waiting for 30 minutes or more to see your doctor is a relic of the past thanks to virtual medical appointments through our computers and phones.

And it’s easy to see why.

What’s referred to as “telemedicine” can save patients nearly two hours of their time, according to Forbes.

Being in the comfort of their own homes is also a major selling point, as a Doctor.com survey found that 91% of the respondents said telemedicine would:

  • Help them stick to their appointments.
  • Manage prescriptions and refills.
  • Follow wellness regimens suggested by their doctor.

Keep in mind folks that telemedicine was becoming more commonplace, and then COVID-19 sent it into overdrive.

As far as hard numbers go, telemedicine forecasts B.C. (before coronavirus) show this market is only getting more valuable, climbing 127% from $35.5 billion dollars to $80.6 billion by 2025.

So those estimates could be too conservative, and I don’t want you to wait around to make money as this market gets bigger and bigger.

The good news is there’s a fire sale going on in the telemedicine market that we can take advantage of right now that will pave your road to wealth.

I’m talking about Teledoc Health Inc. (TDOC), which got slammed on August 5, closing down 19%.

The reason was that the firm is making a big buyout, one that I think is very savvy.

If everyone else takes that as a sign to sell, all the better for us…

A “Super Vaccine” Deal Has Gone into Overdrive After This Latest News

1 | By Michael A. Robinson

The COVID-19 pandemic is and has been an unprecedented event, but there’s also something else to think about.

During this moment in history, we have never had a unified global effort quite like this to find an effective vaccine, and the convergence of technology and medicine that we have access to is allowing researchers to work on a vaccine at break-neck speed.

As of this writing, there are currently 28 COVID-19 vaccines in human trials, and the Trump Administration believes it will have an effective vaccine by 2021.

To get there, the federal government is spending an unprecedented $10 billion

The “Super Vaccine” and Your 10X Profit Potential Within the Next Year

0 | By Strategic Tech Investor Staff

From scientists to business leaders, there’s one thing most people can agree on – life will not return to normal and our economy will not reach maximum production until a vaccine for COVID-19 is in hand. To find this vaccine, the convergence between tech and medicine is creating a biotechnology revolution.

Operation Warp Speed (OWS), an initiative in the United States, aims to deliver over 300 million doses of a safe, effective vaccine for COVID-19 by January 19, 2021.

And as of this writing, what we call a new, viable “Super Vaccine” is pushing to begin production of up to one billion doses. Right now, a tiny company behind the Super-Vaccine has a mere $60 million a year in sales.

But with production expected to begin imminently, it could create a staggering 58,300% revenue surge by year’s end